×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Coronavirus | who | study | anti inflammatory | covid | patients

WHO-Led Trial to Study 3 Anti-inflammatory Drugs for COVID Patients

test tubes filled with blood sit in tray
(LUIS ROBAYO/AFP via Getty Images)

Wednesday, 11 August 2021 08:48 AM

The World Health Organization (WHO) said on Wednesday a clinical trial in 52 countries would study three anti-inflammatory drugs as potential treatments for COVID-19 patients.

"These therapies — artesunate, imatinib, and infliximab — were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients," it said in a statement on the Solidarity PLUS trial.

Artesunate is already used for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.

The original Solidarity trial last year found that all four treatments evaluated — remdesivir, hydroxychloroquine, lopinavir/ritonavir, and interferon — had little or no effect in helping COVID patients.

So far, only corticosteroids have been proven effective against severe and critical COVID-19.

The WHO said artesunate, produced by Ipca, is used to treat malaria. In the trial, it will be administered intravenously for seven days, using the standard dose recommended for the treatment of severe malaria.

Imatinib, produced by Novartis, is used to treat certain cancers. In the trial, it will be administered orally, once daily, for 14 days.

Infliximab, produced by Johnson and Johnson, is used to treat diseases of the immune system. In the trial, it will be administered intravenously as a single dose. 

© 2021 Thomson/Reuters. All rights reserved.


Health-News
The World Health Organization (WHO) said on Wednesday a clinical trial in 52 countries would study three anti-inflammatory drugs as potential treatments for COVID-19 patients...
who, study, anti inflammatory, covid, patients
210
2021-48-11
Wednesday, 11 August 2021 08:48 AM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved